 Strategic report
1 Highlights of our year
2 About us
4 Chairman’s introduction
6 Our business model
7	 Chief	Executive	Officer’s	review
10 Our markets
12 Our strategic priorities
14 Our KPIs
15 Our risks
20  Sustainability
22	 Our	financials
Corporate governance
29	 Chairman’s	governance	overview
30  Directors and Company Secretary
32  Corporate governance report
37 Audit and Risk Committee
40 Nomination Committee
41 Remuneration report
55 Directors’ report
Financial statements
59 Independent auditors’ report
65 Consolidated income statement
65  Consolidated statement of comprehensive income
66 Consolidated balance sheet
67 Consolidated statement of changes in equity
68	 Consolidated	cash	flow	statement
69	 Notes	to	the	financial	statements
97 Company balance sheet
98 Company statement of changes in equity
99	 Notes	to	the	Company	financial	statements
107 Technical glossary
108 Corporate directory
108 Shareholder information
Financial highlights
•  Total revenue increased 26.5% on a reported basis to  
£217.1m (FY 2016: £171.7m). On a constant exchange rate 
(CER)
1
	 basis 	 the 	 increase 	 was 	 9.9%
2
, meeting our full year guidance
•  Catalogue revenue increased by 27.4% on a reported basis 
to £202.5m (FY 2016: £159.0m) and 10.8% on a CER basis
•  RabMAb
®
 primary antibody and non-primary antibody 
revenues	grew	on	a	reported	basis	by	43.9%	and	33.0%,	
and 25.2% and 15.6% on a CER basis, respectively, both 
delivering on our key performance indicator (KPI) targets
• 	 Reported	gross	margin	of	70.1%	following	the	reclassification	
of certain costs
3
 (FY 2016: 70.2%). On a like for like basis FY 2016 
gross	margin	was	69.2%
• EBITDA	margin	was	32.5%	(FY	2016:	33.6%).	Adjusted	EBITDA	
margin
4
	was	33.8%	(FY	2016:	34.9%),	reflecting	the	continued	
investment in the business
• Profit	before	tax	(PBT)	on	a	reported	basis	was	£51.9m	
(FY 2016: £45.4m) and £64.6m (FY 2016: £53.8m) on an 
adjusted	basis
5
•  Reported diluted earnings per share (EPS) increased by 11.9% 
to	20.74	pence	(FY	2016:	18.53	pence).	Adjusted	diluted	EPS
6
 
increased by 13.9% to 25.46 pence (FY 2016: 22.35 pence)
• 	 Closing	cash	and	cash	equivalents	and	term	deposits	were	
£84.8m (30 June 2016: £70.7m)
•  Proposed full year dividend increase of 14% to 10.18 pence 
per share (FY 2016: 8.91 pence)
Operational highlights
•  Continued to gain market share globally as a result of our 
direct customer focus and digital marketing leadership 
•  Led stakeholder discussions to raise industry quality standards 
through knockout validation, expansion of recombinant 
antibody portfolio, and other quality initiatives 
•  Expanded use of the FirePlex
®
 (formerly Firefly
®
)	platform	within	
the kits/assays range by introducing 142 validated antibody pairs 
and validated a range of these pairs in multiplex immunoassays
•  Further expanded our addressable market in custom 
products and licensing by providing ‘Abcam Inside’ for multiple 
pharmaceutical and diagnostic development partners 
•  Accelerated AxioMx technology milestone payments in 
recognition	of	technical	success	demonstrated	with	the	
unique antibody development capabilities at AxioMx
•  Launched several of the Oracle Cloud modules of our 
new	ERP	system	and	made	good	progress	towards	
full implementation in FY 2018
•  Completed recruitment of the Executive Leadership Team 
with	the	appointment	of	a	new	CFO	as	well	as	new	hires	
of Senior VP of Technology and Senior VP of Global 
Manufacturing & Supply Chain
•  Commissioned construction of Abcam’s purpose-built global 
HQ at the expanding Biomedical Campus in Cambridge, UK, 
with	expected	occupancy	in	FY	2019
1   Constant currency is calculated by applying prior period’s actual exchange 
rates to this period’s results.
2	 	 Unaudited	figures	 in	our	pre-close	updat e	stated	10.2%	revenue	growth.	As	a	
result 	 of 	 the 	 completion 	 of 	 the 	 year-end 	 financial 	 review 	 and 	 audit, 	 actual 	 total	
revenue	growth	in	the	year	is	9.9%.
3	 	 This	refe rs	to	goods -in	processing	costs,	w hich	are	costs	incurred	in	receiving,	
resizing and storing brought-in product. These costs are only incurred in relation 
to selling product and management has concluded that it is more appropriate 
to include the costs in gross margin as a cost of sales to give a more accurate 
representation of the true cost of product sales. These costs had previously 
been	shown	as	an	operating	expense.
4  Excluding acquisition and integration costs, the change in fair value of contingent 
consideration, 	 the 	 initial 	 incremental 	 costs 	 associated 	 with 	 the 	 systems 	 and 	 process	
improvements and R&D tax credits relating to prior years.
5  Excluding acquisition and integration costs, the change in fair value of contingent 
consideration, 	 unwinding 	 of 	 discount 	 factor 	 on 	 contingent 	 consideration 	 and 	 fees,	
amortisation of acquisition-related intangible assets, the initial incremental costs 
associated	with	the	systems	and	process	improvements	and	R&D	tax	credits	
relating to prior years.
6  Excluding acquisition and integration costs, the initial incremental costs 
of	systems	and	process	improvements,	unwinding	of	discount	factor	on	
contingent consideration and fees, the change in fair value of contingent 
consideration, amortisation of acquisition-related intangible assets, R&D tax 
credits	relating	to	prior	years	and	the	tax	effect	of	adjusting	items.
1 Annual Report and Accounts 2017 Abcam plc
Strategic report
Highlights of our year
